Sr One Capital Management, Llc bought $2.4M of Zenas BioPharma (ZBIO)
Executed Oct 9 2025, disclosed Oct 14 2025, 5 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 14 2025), the stock returned +35.5% (delay-adjusted); from the execution session (Oct 9 2025), +23.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Sr One Capital Management, Llc (10% owner) filed 3 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 0 sales), most often in ADARx Pharmaceuticals, Inc. (ADRX). Across 3 priced purchase filings, the average 21-session return was -2.6% from execution and -3.5% from disclosure (delay-adjusted; derived). The largest single filing was $27.2M of ADRX (1,600,000 sh across 3 lots, as filed), executed Sep 28.
Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→